HCW Biologics HCWB 深 沪
等待开盘 10-14 09:30:00 美东时间
1.26
-0.220
-14.86%
华盛通- 最 高1.45
- 今 开1.30
- 成交量 213.64万股
- 最 低 1.25
- 昨 收 1.48
- 总市值 281.78万
- 52周最高 23.94
- 市盈率 静 --
- 换手率 95.53%
- 52周最低 1.25
- 委 比 75.00%
- 总股本 223.63万
- 历史最高 1866.00
- 量 比 44.92
- 振 幅 13.51%
- 历史最低 1.25
- 每 手 1
- 风险率 6.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
HCW Biologics Inc. announced progress toward filing an IND application for HCW11-018b, a second-generation T-Cell Engager candidate, in 1H 2027. The drug incorporates BiTE, IL-15, and TGFβRII trap components to address solid tumor challenges. FDA guidance from a Type B meeting supports IND preparation, while manufacturing of clinical trial materials is ongoing.
10-09 13:00
HCW Biologics Prices $1.5M Private Placement Of 903,614 Units At $1.6599 Per Unit
Company agreed to issue and sell an aggregate of 903,614 units (the "Units"), with each Unit consisting of (i) one pre-funded warrant (a "Pre-Funded Warrant") to purchase one share of the Company’s common stock, par value $0.0001 per share, ("Common Stock") and (ii) the right to receive one common s...
09-24 20:28
HCW Biologics signs global HCW11-006 distribution deal
HCW Biologics ( ($HCWB) ) has provided an update. On September 4, 2026, HCW Bio...
09-08 21:51
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW9302, a best-in-class IL-2-based immunotherapeutic, targets autoimmune diseases by expanding and activating regulatory T cells. The U.S. Patent and Trademark Office has granted a patent for its use in treating alopecia areata. Currently, a Phase 1 clinical trial is underway, showing encouraging results with patients responding positively to a single dose. The company has also secured additional patents, strengthening its intellectual property ...
09-02 13:00
HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infections
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research...
08-25 21:02
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
HCW Biologics Inc. has developed a novel TGF-β trap and IL-15 fusion protein that promotes expansion of CD8+ T cells and NK cells, showing potential against cancers and viral infections. The company has integrated this innovation into its second-generation fusion immunotherapeutics, including T Cell Engager (TCE) and Immune Checkpoint Inhibitor (ICI) programs, to enhance anti-tumor activity and address senescence-associated dysplasia. The lead ca...
08-25 13:00
HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer...
07-23 20:02
HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseas...
06-26 20:56
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics Inc. (NASDAQ:HCWB) stock fell during Tuesday’s session. The company announced preliminary results from its Phase 1 trial for HCW9302, an IL-2-based treatment for alopecia areata. All participants in the second-dose cohort showed clinical responses after a single dose of the treatment, ...
06-16 22:20
HCW Biologics Files Prospectus For Offering 5.69M Common Shares
https://www.sec.gov/Archives/edgar/data/1828673/000149315226027656/forms-1.htm
06-08 22:13
